Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 665-677

  King, C L ^a   Ramachandran, S ^a   Chaney, S G ^a,b   Collins, L ^b   Swenberg, J A ^b   DeKrafft, K E ^c   Lin, W ^c   Cicurel, L ^d   Barbier, M ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c The University of North Carolina at Chapel Hill   (United States)

^d DEBIOPHARM SA   (Switzerland)

Author keywords

Debio 0507; DNA adducts; LC MS; Oxaliplatin; UPLC MS MS

Indexed keywords

ANTINEOPLASTIC AGENT; CELL DNA; DEBIO 0507; DIAMINOCYCLOHEXANE; DRUG CARRIER; OXALIPLATIN; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL STRAIN HCT116; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; MASS SPECTROMETRY; PRIORITY JOURNAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEOXYADENINE NUCLEOTIDES; DEOXYGUANOSINE; DINUCLEOSIDE PHOSPHATES; DNA ADDUCTS; HCT116 CELLS; HUMANS; ORGANOPLATINUM COMPOUNDS; TANDEM MASS SPECTROMETRY;

EID: 84859784107     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1744-3     Document Type: Article

References (48)

1. Mani S, Graham MA, Bregman DB, Ivy P, Chaney SG (2002) Oxaliplatin: a review of evolving concepts. Cancer Invest 20:246-263 (Pubitemid 34207752)
2. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K (2005) Preparation and biological properties of dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 101:223-232 (Pubitemid 39600985)
3. Mignard C, Bari V, Bichat F, Cicurel, L, Vaugniaux G, Barbier M (2010) PK and antitumor activity of DEBIO 0507, a new platinum derivative, in preclinical tumor models. American Association For Cancer Research annual meeting, Abstract 571: http://www.educationbook.aacrjournals.org/archive/2010.dtl
4. Cabral H, Nishiyama N, Kataoka K (2007) Optimization of (1,2-diamino-cyclohexane)platinum(II)-loaded polymeric micelles directed to improve tumor targeting and enhanced antitumor activity. J Control Release 121:146-155 (Pubitemid 47212536)
5. Chaney SG, Campbell SL, Bassett E, Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:L3-L11
6. Jennerwein MM, Eastman A, Khokhar AR (1989) Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexes. Chem-Biol Interact 70:39-49 (Pubitemid 19161213)
7. Page JD, Husain I, Sancar A, Chaney SG (1990) Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry 29:1016-1024 (Pubitemid 20053817)
8. Springler B, Whittington DA, Lippard SJ (2001) 2.4 A crystal structure of an oxaliplatin 1,2-d(GpG) intrastrand crosslink in a DNA dodecamer duplex. Inorg Chem 40:5596-5602 (Pubitemid 32999342)
9. Wu Y, Pradham P, Havener J, Boysen G, Swenberg JA, Campbell SL, Chaney SG (2004) NMR solution structure of an oxaliplatin 1,2-d(GpG) intrastrand crosslink in a DNA dodecamer duplex. J Mol Biol 341:1251-1269 (Pubitemid 39092313)
10. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG (2007) Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastrand crosslinks reveal differences in their conformational dynamics. J Mol Biol 373:1123-1140 (Pubitemid 47539475)
11. Treiber DK, Zhai X, Jantzen HM, Essigmann JM (1994) Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF. Proc Natl Acad Sci USA 91:5672-5676 (Pubitemid 24174390)
12. Ohndorf U-M, Rould MA, He Q, Pabo CO, Lippard SJ (1999) Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins. Nature 399:708-712 (Pubitemid 29289069)
13. Wei M, Cohen SM, Silverman AP, Lippard SJ (2001) Effects of spectator ligands on the specific recognition of intrastrand platinum-DNA cross-links by high mobility group box and TATAbinding proteins. J Biol Chem 276:38774-38780
14. Zdraveski ZZ, Mello JA, Farinelli CK, Essigmann JM, Marinus MG (2002) MutS preferentially recognizes cisplatin- over oxaliplatin-modified DNA. J Biol Chem 277:1255-1260 (Pubitemid 34968877)
15. Jung Y, Lippard SJ (2003) Nature of full length HMGB1 binding to cisplatin-modified DNA. Biochemistry 42:2664-2671 (Pubitemid 36330620)
16. Malina J, Novakova O, Vojtiskova M, Natille G, Brabek V (2007) Conformation of DNA intrastrand cross-links of antitumor oxaliplatin and its enantiomeric analog. Biophys J 93: 3950-3962 (Pubitemid 350223811)
17. Chvalova K, Sari MA, Bombard S, Kozelka J (2008) LEF-1 recognition of platinated DNA sequences within double stranded DNA. Influence of flanking bases. J Inorg Biochem 102:242-250
18. Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A (1994) HMG-domain proteins inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci USA 91:10394-10398 (Pubitemid 24329003)
19. Fink D, Nebel S, Aebi S, Zheng H, Cenni B et al (1996) The role of mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886 (Pubitemid 26374423)
20. Vaisman A, Varchenko M, Umar A, Kunkel TA, Risinger JI, Barrett JC, Hamilton TC, Chaney SG (1998) The role of hMLH1, hMSH3 and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58:3579-3585 (Pubitemid 28376554)
21. Zhai X, Beckmann H, Jantzen HM, Essigmann JM (1998) Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor. Biochemistry 37:16307-16315 (Pubitemid 28536267)
22. Vaisman A, Lim SE, Patrick SM, Copeland WC, Hinkle DC, Turchi JJ, Chaney SG (1999) Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. Biochemistry 38:11026-11039
23. Butour J-L, Johnson NP (1986) Chemical reactivity of monofunctional platinum-DNA adducts. Biochemistry 25:4534-4539 (Pubitemid 16010188)
24. 195Pt NMR kinetic and mechanistic studies of cis- and trans-diamminedichloroplatinum(II) binding to DNA. J Am Chem Soc 112:6860-6871
25. 2] and DNA in vitro. J Am Chem Soc 107:6376-6380
26. Butour JL, Mazard AM, Macquet JP (1985) Kinetics of the reaction of cis-platinum compounds with DNA in vitro. Biochem Biophys Res Commun 133:347-353 (Pubitemid 16155366)
27. Knox RJ, Friedlos F, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis- diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato) platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res 46:1972-1979 (Pubitemid 16080411)
28. Mauldin SK, Plescia M, Richard FA, Wyrick SD, Voyksner RD, Chaney SG (1988) Displacement of the bidentate malonate ligand from (d, l-trans-1,2-diaminocyclohexane)malonatoplatinum(II) by physiologically important compounds in vitro. Biochem Pharmacol 37:3321-3333
29. Mauldin SK, Gibbons G, Wyrick SD, Chaney SG (1988) Intracellular biotransformation of platinum compounds with the 1,2-diaminocyclohexane carrier ligand in the L1210 cell line. Cancer Res 48:5136-5144
30. Luo FR, Wyrick SD, Chaney SG (1999) Biotransformations of oxaliplatin in rat blood in vitro. J Biochem Molec Toxicol 13:159-169 (Pubitemid 129705388)
31. Luo FR, Wyrick SD, Chaney SG (1998) Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res 10:595-603 (Pubitemid 128740448)
32. Segal E, Le Pecq J-B (1985) Role of ligand exchange processes in the reaction kinetics of the antitumor drug cis-diamminedichloroplatinum(II) with its targets. Cancer Res 45:492-498 (Pubitemid 15161033)
33. Davies MS, Berners-Price S, Hambley TW (1998) Rates of platination of AG and GG containing double-stranded oligonucleotides: Insights into why cisplatin binds to GG and AG but not GA sequences in DNA. J Am Chem Soc 120:11380-11390 (Pubitemid 28531081)
34. Hah SS, Stivers KM, de Vere White RW, Henderson PT (2006) Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol 19:622-626 (Pubitemid 43800978)
35. Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT (2007) Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem Res Toxicol 20:1745-1751
36. Hah SS, Henderson PT, Turteltaub KW (2010) Towards biomarker-dependent individualized chemotherapy: exploring cell-specific differences in oxaliplatin-DNA adduct distribution using accelerator mass spectrometry. Biorg Med Chem Lett 20:2448-2451
37. Fichtinger-Schepman AMJ, van Dijk-Knijnenburg HCM, van der Velde-Visser SD, Berends F, Baan RA (1995) Cisplatin and carboplatin-DNA adducts: is Pt-AG the cytotoxic lesion? Carcinogenesis 16:2447-2453
38. Blommaert FA, van Dijk-Knijnenburg HCM, Dijt FJ, Denengelse L, Baan RA, Berends F, Fichtinger-Schepman AMJ (1995) Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells. Biochemistry 34:8474-8480
39. Boudny V, Vrana O, Gaucheron F, Kleinwachter V, Leng M, Brabec V (1992) Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. Nucleic Acids Res 20:267-272
40. Saris CP, van de Vaart PJM, Rietbroek RC, Blommaert FA (1996) In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17:2763-2769 (Pubitemid 27037637)
41. Woynarowski JM, Chapman WG, Napier C, Herzig MCS, Juniewicz P (1998) Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Molec Pharmacol 54:770-777 (Pubitemid 28523169)
42. Luo FR, Yen TY, Wyrick SD, Chaney SG (1999) High-performance liquid chromatographic separation of the biotransformation products of oxaliplatin. J Chromatog B 724:345-356 (Pubitemid 29148096)
43. Le Pla RC, Ritchie KJ, Henderson CJ, Wolf CR, Harrington CF, Farmer PB (2007) Development of a liquid chromatography-electrospray ionization tandem mass spectrometry method for detecting oxaliplatin-DNA intrastrand cross-links in biological samples. Chem Res Toxicol 20:1177-1182 (Pubitemid 47372998)
44. Mowaka S, Linschied M (2008) Separation and characterization of oxaliplatin dinucleotides from DNA using HPLC-ESI-ion trap mass spectrometry. Anal Bioanal Chem 392:819-830
45. Kerr SL, Shoeib T, Sharp BL (2008) A study of oxaliplatin-nucleobase interactions using ion trap electrospray mass spectrometry. Anal Bioanal Chem 391:2339-2348
46. Baskerville-Abraham IM, Boysen G, Troutman JM, Mutlu E, Collins L, deKrafft KE, Lin W, King C, Chaney SG, Swenberg JA (2009) Development of an ultraperformance liquid chromatography/mass spectrometry method to quantify cisplatin 1,2 intrastrand guanine-guanine adducts. Chem Res Toxicol 22:905-912
47. Eastman A (1983) Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine) platinum(II). Biochemistry 22:3927-3933
48. Eastman A (1986) Reevaluation of the interactions of cis- diamminedichloro(ethylenediamine)platinum(II) with DNA. Biochemistry 25:3912-3915